#eswatini

#eswatini

The freezer is filled with blue-lidded tubes of cows' blood, ready to be defrosted and used to feed the colony of mosquitoes. Nombuso Princess Bhembe tends the mosquitoes at Eswatini's national insectary, part of the southern African country's push to eliminate malaria.

On that sunny March morning, in a small health center in Lobamba, a rural area of Eswatini, this 32-year-old sex worker has just become one of the first people in the world to receive lenacapavir, a drug that, administered twice a year, offers nearly 100% protection against HIV.

Eswatini on Tuesday became the first African country to receive lenacapavir, the first twice-yearly HIV prevention injection hailed by global health officials as a game-changer in the fight against a virus that has killed tens of millions of people across the continent. Developed by Gilead Sciences, lenacapavir has demonstrated near-total protection in clinical studies. Its rollout, initially planned for 10 high-risk African countries, is part of the U.S. President's Emergency Plan for AIDS Relief, or PEPFAR, in partnership with the Global Fund. By 2027, the initiative aims to benefit at least 2 million people in those countries.

The deported group included individuals described as 'so uniquely barbaric that their home countries refused to take them back,' an assertion the Jamaican government strongly refutes.